Gentian Diagnostics

GENT

NO0010748866

Medical Equipment, Supplies & Distribution

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-21 am EDT			5-day change	1st Jan Change
37.6 ^NOK	-1.05%		-0.53%	-9.40%

Apr. 30	Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	Transcript : Gentian Diagnostics ASA, Q1 2024 Earnings Call, Apr 30, 2024

Gentian Diagnostics as Provides Sales Guidance for the Year 2019

November 07, 2019 at 07:17 am EST

Gentian Diagnostics AS provided sales guidance for the year 2019. The company expects continued sales growth in 2019 versus 2018 primarily driven by fCAL® turbo.

Latest news about Gentian Diagnostics

Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 30	CI
Transcript : Gentian Diagnostics ASA, Q1 2024 Earnings Call, Apr 30, 2024	Apr. 30
Gentian Diagnostics Asa Resolves to Elect Ms. Hilja Ibert as Chairperson of the Board of Directors	Apr. 29	CI
Gentian Diagnostics ASA Appoints Mr. Njaal Kind as Acting CEO	Apr. 29	CI
Gentian Diagnostics ASA Announces Resignation of Hilja Ibert as CEO, Effective on April 29, 2024	Mar. 21	CI
Tomas Settevik Not to Stand for Re-Election as Chairperson of Gentian Diagnostics ASA, Effective April 29, 2024	Mar. 21	CI
Gentian Diagnostics' CEO Resigns, Wins Recommendation to Succeed Chair	Mar. 21	MT
Gentian Diagnostics ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 09	CI
Transcript : Gentian Diagnostics ASA, Q4 2023 Earnings Call, Feb 09, 2024	Feb. 09
Gentian Diagnostics Asa Announces Resignation of Frank Frantzen from the Board of Directors	Dec. 18	CI
Gentian Diagnostics ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Transcript : Gentian Diagnostics ASA, Q3 2023 Earnings Call, Oct 26, 2023	23-10-26
Gentian Diagnostics ASA Expands Product Portfolio With Turbidimetric Retinol-Binding Protein Immunoassay	23-09-29	CI
Gentian Diagnostics ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Transcript : Gentian Diagnostics ASA, Q2 2023 Earnings Call, Aug 24, 2023	23-08-24
Gentian Diagnostics ASA (OB:GENT) acquired Getica Ab from Erling Sundrehagen for SEK 2.8 million.	23-07-02	CI
Norway's Gentian Diagnostics Buys Sweden-based Getica in SEK3 Million Deal	23-06-15	MT
Gentian Diagnostics ASA (OB:GENT) entered into an agreement to acquire Getica Ab from Erling Sundrehagen for SEK 3 million.	23-06-14	CI
Transcript : Gentian Diagnostics ASA - Analyst/Investor Day	23-05-10
Transcript : Gentian Diagnostics ASA, Q1 2023 Earnings Call, May 05, 2023	23-05-05
Gentian Diagnostics ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Gentian Diagnostics ASA Announces Results from Study on Health Economic Impact of Use of GCAL CalProtectin Immunoassay for Early Detection of Infection in Intensive Care Patients	23-03-22	CI
Transcript : Gentian Diagnostics ASA, Q4 2022 Earnings Call, Feb 16, 2023	23-02-16
Gentian Diagnostics ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-16	CI
Gentian Diagnostics ASA Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-16	CI

Gentian Diagnostics ASA is a Norway-based company within health care sector. The Company develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Companyâs product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The Company is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-29 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Gentian Diagnostics

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

38 NOK

Average target price

57 NOK

Spread / Average Target

+50.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GENTIAN DIAGNOSTICS	-9.40%	54.84M
BIOMÉRIEUX	-6.26%	12.23B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.93%	8.17B
DIASORIN S.P.A.	+7.10%	5.78B
LANTHEUS HOLDINGS, INC.	+31.24%	5.74B
AUTOBIO DIAGNOSTICS CO., LTD.	-7.47%	4.24B
10X GENOMICS, INC.	-56.50%	2.97B
ANDON HEALTH CO., LTD.	+12.56%	2.73B
VITROLIFE AB	-4.67%	2.38B
MYRIAD GENETICS, INC.	+28.00%	2.26B

Diagnostic & Testing Substances